PMHS
Polomar Health Services, Inc.0.0800
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.24MP/E (TTM)
-Basic EPS (TTM)
-0.09Dividend Yield
0%Recent Filings
8-K
Amends ForHumanity deal
Polomar Health Services executed a Second Amendment to its product fulfillment agreement with ForHumanity and Island Group 40, effective December 5, 2025, extending initial exclusivity to June 30, 2026, with further extensions tied to revenue milestones like $1.75M by June 30, 2026, and $5M for 2026. Guaranteed payments schedule $100K due December 8, $200K December 29, $200K January 12, 2026; Polomar received $350K already. Exclusivity hinges on sales targets. ForHumanity must hit them.
10-Q
Q3 FY2025 results
Polomar Health logged Q3 revenue of $6.2k, down from $9.8k y/y (derived), with gross profit shrinking to $4.3k yet margins holding at 70.1%. Operating expenses ballooned to $633k from $268k y/y, driven by G&A (legal, accounting, payroll per MD&A), yielding a $629k operating loss widened by stock-based comp and amortization; net loss hit $650k versus $271k y/y, with the $21k delta mainly from interest. Cash climbed to $39k on $619k related-party notes, funding $586k operating burn YTD; related debt totals $994k at 12% due 2025-27. New CareValidate GLP-1 deal starts Q4. Going concern doubts persist.
8-K
Merger amendment details
Polomar Health Services amended its July 23, 2025 merger agreement with Altanine Inc. on October 8, 2025, setting a one-for-one exchange of common stock shares and five preferred shares for each Altanine preferred share, subject to adjustment. This tweak refines the deal structure amid ongoing integration. No financial terms disclosed. Deal advances steadily.
8-K
Amended exclusivity deal signed
Polomar Health Services executed an Amended and Restated Product Fulfillment and Distribution Agreement on August 25, 2025, effective August 19, granting ForHumanity exclusive U.S. marketing rights for its patent-pending inhalable sildenafil and eletriptan through March 31, 2026, in exchange for guaranteed payments totaling $750,000—$200,000 already received—with potential extensions tied to revenue milestones up to $20 million by 2027. The 42-month deal, running to September 16, 2028, positions Polomar to fulfill prescriptions via its specialty pharmacy while IG4 handles account management, aiming to boost sales through ForHumanity's telemedicine network. Exclusivity hinges on hitting targets. Patent approval remains uncertain.
10-Q
Q2 FY2025 results
Polomar Health Services posted Q2 revenue of $5,470, down sharply from $14,495 a year earlier, while six-month totals slid to $10,011 from $28,105, reflecting the post-merger shift to an online model. Gross profit shrank to $3,832 from $10,256, but operating expenses ballooned 182% to $567,165, driven by legal fees, amortization, payroll, and $109,231 in stock-based compensation, yielding an operating loss of $563,333 versus $190,742 last year. Net loss widened to $605,563, or $0.02 per diluted share on 27,667,155 shares, with the extra $42,230 hit from interest expense. Cash dwindled to $4,678 amid $233,357 in operating outflows, offset by $231,844 from related-party notes; related-party debt stood at $597,550, maturing July 2027 at 12%. The September 2024 Polomar merger, a reverse recapitalization, integrated pharmacy operations without disclosed goodwill. Revenue remains vulnerable to regulatory hurdles in expanding state licenses.
BLMH
Blum Holdings Inc.
0.72-0.01
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
CPMD
Cannapharmarx Inc.
0.00-0.00
HIMS
Hims & Hers Health, Inc.
36.86+0.61
MGRX
Mangoceuticals, Inc.
1.20+0.06
PETS
PetMed Express, Inc.
3.90+1.03
PLMR
Palomar Holdings, Inc.
127.54+2.02
PNPL
Pineapple, Inc.
0.13+0.00
SRXH
SRX Health Solutions, Inc.
0.38+0.07
WGRX
Wellgistics Health, Inc.
0.54-0.04